Background-Pulmonary arterial hypertension is a progressive proliferative vasculopathy of the small pulmonary arteries that is characterized by a primary failure of the endothelial nitric oxide and prostacyclin vasodilator pathways, coupled with dysregulated cellular proliferation. We have recently discovered that the endogenous anion salt nitrite is converted to nitric oxide in the setting of physiological and pathological hypoxia. Considering the fact that nitric oxide exhibits vasoprotective properties, we examined the effects of nitrite on experimental pulmonary arterial hypertension. Methods and Results-We exposed mice and rats with hypoxia or monocrotaline-induced pulmonary arterial hypertension to low doses of nebulized nitrite (1.5 mg/min) 1 or 3 times a week. This dose minimally increased plasma and lung nitrite levels yet completely prevented or reversed pulmonary arterial hypertension and pathological right ventricular hypertrophy and failure. In vitro and in vivo studies revealed that nitrite in the lung was metabolized directly to nitric oxide in a process significantly enhanced under hypoxia and found to be dependent on the enzymatic action of xanthine oxidoreductase. Additionally, physiological levels of nitrite inhibited hypoxia-induced proliferation of cultured pulmonary artery smooth muscle cells via the nitric oxide-dependent induction of the cyclin-dependent kinase inhibitor p21 Waf1/Cip1 . The therapeutic effect of nitrite on hypoxia-induced pulmonary hypertension was significantly reduced in the p21-knockout mouse; however, nitrite still reduced pressures and right ventricular pathological remodeling, indicating the existence of p21-independent effects as well. Conclusion-These studies reveal a potent effect of inhaled nitrite that limits pathological pulmonary arterial hypertrophy and cellular proliferation in the setting of experimental pulmonary arterial hypertension. (Circulation. 2010;121:98-109.)
P ulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries that is characterized by vascular proliferation and remodeling that results in increased pulmonary vascular resistance. 1 This progressively leads to right heart failure and ultimately death. 2 PAH can be classified as primary or secondary pulmonary hypertension; however, despite classification, common pathophysiological features exist, including pulmonary vessel wall remodeling, vasoconstriction, and thrombosis in situ. 3 The cellular and molecular events underlying the evolution of these changes and those that occur in response to these changes are under investigation and continue to guide the development of therapeutics. 4 A number of central molecules and molecular pathways have been implicated, but clearly, the pathogenesis involves a multifactorial process.
Clinical Perspective on p 109
One major pathway involved in the abnormal proliferation and contraction of pulmonary vascular smooth muscle cells is the nitric oxide (NO) pathway. [5] [6] [7] [8] NO is endogenously produced in the vascular endothelium by NO synthases with L-arginine used as a substrate. 6 The vasoregulatory properties of NO have been well characterized and include vasodilation, inhibition of smooth muscle cell proliferation and migration, and antiplatelet effects. PAH is associated with decreased bioavailability and responsiveness to NO. 9 -14 The decreased bioavailability of NO may occur secondary to impaired formation of NO, caused by decreased endothelial NO synthase expression, endothelial NO synthase uncoupling, and dysregulated L-arginine metabolism, coupled with the increased consumption of NO by reactive oxygen species.
Mechanistic studies of NO-mediated inhibition of smooth muscle cell proliferation have been shown to use both cGMPdependent and -independent signaling. Multiple studies have highlighted an essential role for the cyclin-dependent kinase inhibitor p21 Waf1/Cip1 in NO-mediated inhibition of smooth muscle cell proliferation, [15] [16] [17] including studies of pulmonary vascular smooth muscle cells under conditions of hypoxia. 18 Furthermore, the vascular proliferative lesions in experimental PAH are known to involve decreased levels of p21 Waf1/Cip1 and other cyclin-dependent kinase inhibitors. 19, 20 Because PAH is associated with a decreased bioavailability of NO, targeting of the NO pathway has been proposed as a potential therapy. 21, 22 In experimental models, inhaled NO limits the development of PAH. Additionally, long-term inhaled NO has been used clinically in patients with PAH in small case series; however, inhaled NO therapy is cumbersome and is associated with hemodynamic deterioration when its use is interrupted. 23, 24 Furthermore, inhaled NO gas has a limited therapeutic window in terms of dose and duration of exposure. NO synthase overexpression by protein or gene transfer may be of limited utility on the basis of the requirement for oxygen as a substrate for NO synthesis. Other reports have suggested that treatment with L-arginine reduces pulmonary artery pressure and increases exercise tolerance in patients with PAH [25] [26] [27] [28] ; however, definitive placebocontrolled studies have not shown efficacy.
The circulating molecule nitrite (NO 2 Ϫ ), which was once thought to be a stable product of NO metabolism, is now recognized as an important endocrine reservoir of NO. 29 Nitrite is reduced to bioactive NO along a physiological pH and oxygen gradient by several mechanisms, including enzymatic reduction by hemoglobin and myoglobin, components of the mitochondrial electron transport chain, and xanthine oxidoreductase (XOR). 30 -35 Nitrite is known to limit ischemia/reperfusion-induced apoptosis and cytotoxicity in heart, liver, and brain. 34,36 -39 Additionally, nitrite has been shown to mediate hypoxic pulmonary vasodilation in a deoxyhemoglobinand pH-dependent fashion. 40 Given the central role of NO in vasoregulation and the association of decreased NO bioavailability in PAH, together with the known effects of nitrite, we hypothesized that low-dose nebulized nitrite prevents or reverses experimental PAH and that the hypoxic metabolism of nitrite to NO is dependent on XOR.
Methods

Inhaled Nitrite Treatment
Sodium nitrite (3 to 300 mg; Sigma Chemical Co, St Louis, Mo) was nebulized in PBS (pH 7.4; 5 mL) into a Plexiglas living environment measuring 24ϫ10ϫ9 in. A diffuser was placed in front of the inlet to allow equal distribution of nebulized droplets, and a controlled fan pulled air through the environment at a flow rate of 129 cu ft/min.
Monocrotaline Sodium Model of PAH
Monocrotaline sodium (Sigma-Aldrich), dissolved in 1N HCl neutralized with 0.5N NaOH and diluted with PBS, was given as a single 50-mg/kg SC injection to male Sprague-Dawley rats weighing between 250 and 260 g (Harlan, Indianapolis, Ind). Control rats were injected with the same volume of saline.
Chronic Hypoxia Model of PAH
Male C57BL/6, S129, or cdkn1 Ϫ/Ϫ mice (The Jackson Laboratory, Bar Harbor, Me) were purchased and allowed to acclimate for 1 week with access to food and water ad libitum. Mice were placed in an airtight Plexiglas chamber and exposed to 10% O 2 continuously for 4 weeks. For sodium nitrite or vehicle nebulization, mice were removed and placed in another airtight chamber and exposed to nebulized sodium nitrite (30 mg in 5 mL PBS over 20 minutes) or the same volume of saline alone and then immediately returned to the 10% O 2 chamber. Nitrite nebulization was delivered either 1 or 3 times a week initiated at varying points according to experimental detail.
Hemodynamic and Ventricular Weight Measurements
Hemodynamic and ventricular weight measurements were performed as follows. Briefly, mice were anesthetized with pentobarbital. The trachea was cannulated, and mice were ventilated at room air (tidal volume, 0.01 mL/g). The thoracic cavity was opened; a Millar (Millar Instruments Inc, Houston, Tex) catheter was inserted into the right ventricle (RV); and RV systolic pressure was measured with PowerLab (ADI Instruments, Colorado Springs, Colo) monitoring equipment. For ventricular weight measurement, hearts were excised and atria were removed. The RV free wall was dissected, and each chamber was weighed. The ratio of RV weight to left ventricular (LV) weight plus septum (RV/LVϩS) was used as an index of RV hypertrophy.
Echocardiography
Transthoracic echocardiography was performed after sedation with tribromoethanol (125 mg/kg IP) with a VisualSonics Vevo 770 machine with a 45-MHz transducer. RV wall thickness and RV area were determined.
Lung Histology
Lungs were inflated, and the pulmonary artery was perfused with 4% paraformaldehyde. Excised lungs were fixed in 4% paraformaldehyde for 2 hours at 4°C, washed with PBS containing 30% sucrose, and embedded in optical coherence tomography compound. Frozen sections (12 m) were used for hematoxylin and eosin staining. For pulmonary vascular morphometry, images of terminal arterioles were captured with a microscope digital camera system (Olympus, Central Valley, Pa), and arterial area was measured with an image analysis program (NIH IMAGE 1.55). The diameter of measured vessels ranged between 30 and 40 m. Percent wall thickness was calculated by the following formula: wall thickness (%)ϭarea ext Ϫarea int / area ext ϫ100, where area ext and area int are the area bounded by external and internal elastic lamina, respectively. Ten vessels of comparable size per rat were measured from 6 rats per group.
Collection and Measurement of Plasma, Whole-Blood, and Lung Tissue Nitrite Levels
For plasma nitrite measurements, blood samples were drawn into heparin and centrifuged (5000g for 2 minutes) immediately to avoid nitrite consumption by hemoglobin. Plasma was immediately removed and frozen for later analysis. For whole-blood nitrite measurements, 100 L whole blood was mixed in 400 L nitrite preservation solution containing K 3 Fe(CN) 6 (800 mmol/L), N-ethylmaleimide (100 mmol/L), and Nonidet P-40 (10%). Lung tissue was immediately homogenized in
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a solution containing KCN (1 mmol/L), K 3 Fe(CN) 6 (12 mmol/L), N-ethylmaleimide (10 mmol/L), and DTPA (100 mol/L) and frozen for later analysis. The nitrite concentration in whole blood, plasma, and lung homogenate was measured using triiodine-based reductive chemiluminescence with an NO analyzer (model 280, Sievers Co, Boulder, Colo) as previously described. Protein concentration of each lung homogenate was measured with the Bradford protein assay kit (Pierce Biotechnology, Inc, Rockford, Ill), and nitrite concentration of the lung homogenate was expressed in picomoles per milligram.
NO Generation
NO generation from nitrite (1 mmol/L) in the presence of lung homogenates (1 to 4 mg/mL) was measured in a sealed vessel in which the solution and head space were purged with helium. The vessel was connected in line with an NO analyzer (Sievers Co) as previously described. 34 In some conditions, homogenates were pretreated with allopurinol or superoxide dismutase. NO generation was normalized to tissue protein concentration as measured by the Pierce protein assay kit.
Cell Culture
Primary rat and mouse pulmonary artery smooth muscle cells (PASMCs) were isolated as previously described 41 and cultured in DMEM (low glucose):F12 medium (1:1 vol/vol) with 10% FBS, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin in a 37°C, 5% CO 2 incubator. PASMCs from passages 3 through 7 only were used.
Cellular Proliferation
Growth-arrested PASMCs were stimulated to proliferate with hypoxia (3% O 2 ) with or without platelet-derived growth factor-BB (PDGF BB ; 10 g/mL) in the presence of 5 Ci/mL 3 H-thymidine (NEN, Boston, Mass) for 24 hours. 3 H-thymidine incorporation into trichloroacetic acid-precipitated DNA was quantified by scintillation counting as described. 42
Western Blot Analysis
SDS-PAGE was performed as previously described. After electrophoresis, proteins were transferred to nitrocellulose sheets. These membranes were blocked in 5% milk and incubated with primary (mouse anti-p21) and secondary antibodies as previously described. 42 These proteins were visualized with chemiluminescent reagents (SuperSignal, Pierce).
XOR Activity
XOR activity was determined by use of a previously described fluorometric assay, which is based on the XOR-catalyzed conversion of pterin (2-amino-4-hydroxypteridine, 10 mol/L) to the fluorochrome isoxanthopterin (excitation, 345 nm; emission, 390 nm). 43 XOR activity was determined from lung homogenates and calibrated using a standard curve generated with authentic isoxanthopterin (Sigma). Measurements were performed in a final volume of 600 L in phosphate buffer (K 2 HPO 4 /KH 2 PO 4 50 mmol/L, EDTA 0.1 mmol/L; pH 7.4). Pterin (1 mmol/L) was prepared fresh as a stock solution in 1 mmol/L NaOH. This methodology was confirmed by measurement of uric acid formation via high-performance liquid chromatography with electrochemical detection.
Statistical Analysis
Statistical analyses of all experiments were performed with 1-way analysis of variance (ANOVA), with the Holm-Sidak method used for pairwise comparisons (SigmaPlot, Systat, Chicago, Ill). This method is used to compute a family of pairwise comparisons of interest and then determines an unadjusted P value for each test in the family. These P values are compared with critical values that have been adjusted to allow for the fact that multiple comparisons are being performed. Significance is assumed at ␣ϭ0.050. Values are expressed as meanϮSD. P values are expressed as unadjusted values, which are determined to be significant if they are lower than determined critical values. All unadjusted values of PϽ0.001 are lower than determined critical values and thus reach statistical significance. All other unadjusted P values are reported with corresponding critical values. Normal distribution was determined by the Shapiro-Wilk test, and no departures were identified.
Results
Low-Dose Nebulized Nitrite Prevents or Reverses Chronic Hypoxia-Induced PAH
Exposure of mice to chronic hypoxia (10% oxygen) results in pulmonary vascular remodeling characterized by increased muscularization, leading to increased RV pressures (RVPs) and RV hypertrophy. To induce hypoxia-dependent PAH in our model, C57BL/6 mice were exposed to 10% oxygen continuously for 0 to 4 weeks, and RVPs were measured at weekly intervals. Chronic hypoxia resulted in the development of significantly increased RVPs by 2 weeks (31.7Ϯ3.2 mm Hg; PϽ0.001) compared with baseline (18.4Ϯ2.5 mm Hg), and they increased to 40.3Ϯ5.8 mm Hg by 4 weeks ( Figure 1A) . To determine the effect of inhaled nebulized nitrite in experimental PAH, mice were exposed to hypoxia for 28 days, during which they were treated with inhaled nitrite (1.5 mg/min nebulized into an exposure chamber for 20 minutes) either 1 or 3 times per week throughout the duration of the hypoxia exposure or 3 times per week during days 15 to 28 of hypoxia exposure. PAH was determined by measuring RV hypertrophy (RV/ LVϩS and ratio of RV to body weight), RVPs, and dP/dtmax and echocardiography (RV area and wall thickness). Of note, all RVP measurements were obtained at least 24 hours after nitrite nebulization. Additionally, inhaled nitrite did not significantly alter systemic mean arterial pressure (maximum change, Ϫ2.9Ϯ1.7; Pϭ0.47), consistent with previous findings. 40 Treatment with nebulized nitrite, either 1 or 3 times per week, significantly prevented the development of PAH as determined by all outcome measurements (Figures 1B and 1C and Table 1 ). Additionally, nitrite treatment 2 weeks into the hypoxic exposure, after the establishment of PAH, halted the progression of PAH and reversed increases in RVPs (25.7Ϯ4.0 mm Hg with therapeutic nitrite versus 31.7Ϯ3.2 mm Hg after 2 weeks of hypoxia; PϽ0.001). Thus, inhaled nebulized nitrite inhibited the development of hypoxia-induced PAH and reversed established PAH.
To evaluate the effectiveness of sodium nitrite, a dose response was performed using once-per-week administration. C57BL/6 mice were exposed to chronic hypoxia for 4 weeks. Doses of sodium nitrite ranging from 3 to 300 mg were nebulized into the exposure environment over 20 minutes 1 time per week over the duration of the experiment. Sodium nitrite prevented the development of PAH at all doses tested, but not in a dose-dependent manner ( Table 2) . Protection against the development of PAH by nitrite treatment was significant at all doses as determined by RVP measurements and by RV/LVϩS mass ratios, except for the 10-mg dose, which failed to reach significance using the mass ratio end point. These data suggest that nitrite exerts protective and antiproliferative effects even at the lowest doses used once a week.
Nitrite Reverses Monocrotaline-Induced PAH
To determine whether the effects of nitrite therapy on PAH were specific to chronic hypoxia, we examined an additional model of experimental PAH, monocrotaline sodium-induced PAH. Monocrotaline, a pyrrolizidine alkaloid, is metabolized by the liver to a toxic metabolite that causes progressive pulmonary vascular endothelial injury, resulting in pulmonary vascular inflammation and smooth muscle cell proliferation. Monocrotaline was administered as a single subcutaneous dose (50 mg/kg) to male Sprague-Dawley rats, and the animals were killed 43 days later to assess for PAH. As expected, monocrotaline treatment increased RV hypertrophy, as determined by the RV/LVϩS and RV to body weight mass ratios, compared with controls (0.48Ϯ0.10 and 1.21Ϯ0.32 versus 0.26Ϯ0.05 and 0.62Ϯ0.06, respectively; PϽ0.001; Figures 2A through 2C) . To test the effects of nitrite in this model, sodium nitrite was nebulized as described above (1.5 mg/min for 20 minutes) 3 times per week during weeks 4 to 6 after monocrotaline treatment. Similar to its effects in the chronic hypoxia model of experimental PAH, nitrite reduced monocrotaline-induced PAH (Figures 2A  through 2D ). Nitrite treatment significantly reversed monocrotaline-induced RV hypertrophy compared with monocrotaline alone (RV/LVϩS mass ratioϭ0.29Ϯ0.07; RV to body weight mass ratioϭ0.70Ϯ0.12; PϽ0.001) and protected against monocrotaline-induced increases in RVPs. To determine the influence of nitrite on acute changes in pulmonary vasodilation in this model, rats that had been treated with monocrotaline (50 mg/kg SC) 3 weeks earlier underwent VR catheterization via an internal jugular approach. RVPs were measured at baseline and during and for 30 minutes after nitrite nebulization (1.5 mg/min for 20 minutes). Baseline RVP measurements were 24.2Ϯ2.2 mm Hg. The maximal change in RVP was Ϫ2.3Ϯ0.9 mm Hg. These data suggest a minimal role for acute vasodilatory changes by these low doses of nebulized nitrite and support additional mechanisms of action in the reversal of PAH.
Additionally, histological assessment of pulmonary vascular hyperplasia was determined. Muscularization and hyperplasia of the small pulmonary arteries were assayed by measuring the percentage of the total area of the vessel that was made up of media. Monocrotaline treatment increased the percentage to 54Ϯ12% compared with 19Ϯ4% in controls, whereas nebulized nitrite reversed the effects of monocrotaline, decreasing this to 27Ϯ13% (PϽ0.001; Figure 3A and 3B). 
Nebulized Nitrite Is Rapidly Metabolized in Hypoxic Lung Tissue
To determine the pharmacokinetics of inhaled nitrite in blood and tissue during hypoxia, mice were nebulized with nitrite (1.5 mg nitrite/min) for 20 minutes before being subjected to hypoxia (10%). Nitrite concentrations in whole blood, plasma, and lung were measured at baseline before nebulization and then measured over time (10 minutes to 24 hours) after nebulization ( Figure 4 ). As expected, nitrite levels were elevated in whole blood (1.71Ϯ0.26 mol/L) and plasma (1.49Ϯ0.09 mol/L) at 10 minutes after nitrite administration and then decreased slowly over time. Whole-blood nitrite concentration reached basal levels (1.03Ϯ0.07 mol/L) by 30 minutes (Figure 4A ), whereas plasma nitrite reached basal concentration (0.29Ϯ0.03 mol/L) at 120 minutes ( Figure  4B ). Interestingly, when the mice were subjected to hypoxia, no elevation in nitrite concentration was seen in the lung after nitrite administration compared with baseline (87Ϯ2 pmol/ mg; Figure 4C ). We hypothesized that this result was due to the rapid metabolism of nitrite by the lung during hypoxia. Indeed, nitrite concentration was increased (304Ϯ4 pmol/mg) in normoxic mice but not in hypoxic mice 5 minutes after nitrite inhalation compared with baseline.
Hypoxic Metabolism of Nitrite to NO Is Dependent in Part on XOR
Previous studies have described XOR as a putative nitrite reductase in the lung. To determine the mechanism of the pulmonary hypoxic nitrite metabolism, lung tissue homogenates were put in a sealed chamber that was purged with helium, and NO generation after nitrite (1 mmol/L) addition was measured. On the addition of nitrite, lung tissue generated a significant concentration of NO (12.3Ϯ2.1 pmol NO · min Ϫ1 · mg Ϫ1 protein), which was attenuated (6.2Ϯ3.2 pmol NO · min Ϫ1 · mg Ϫ1 ) by allopurinol (200 mol/L), an inhibitor of XOR ( Figure 5A and 5B) .
XOR is an enzyme that primarily generates superoxide, which will react at the diffusion limit with any NO generated from nitrite reduction, thus potentially reducing bioavailable NO. In this context, nitrite can be considered an alternative electron acceptor from XOR that diverts electrons from oxygen, thus reducing enzymatic superoxide flux. To determine whether nitrite-dependent NO generation was influenced by superoxide formation, NO generation was measured in the presence and absence of superoxide dismutase (300 U/mL). In the presence of superoxide dismutase, NO generation from nitrite was significantly increased (16.3Ϯ4.1 pmol · min Ϫ1 · mg Ϫ1 protein), consistent with concerted interdependent NO and superoxide generation from XOR. Thus, the hypoxic metabolism of nitrite to NO in lung tissue is at least partly dependent on XOR, and the bioavailability of NO in hypoxic lung tissue is modulated by superoxide formation.
To confirm the XOR-dependent hypoxic metabolism of nitrite to NO, the influence of nitrite on NO signaling was investigated. cGMP levels were determined as a marker of NO signaling. Lung homogenates were made hypoxic (1% oxygen) and exposed to nitrite. cGMP levels were increased in hypoxic homogenates exposed to nitrite (PϽ0.001; Figure  5C ). Additionally, allopurinol significantly attenuated cGMP generation, further confirming that NO generation from nitrite is dependent on XOR in the lung under these experimental conditions (PϽ0.001).
Reduction of Smooth Muscle Cell Proliferation by Nitrite Is Dependent on XOR
On the basis of the ability of nitrite to protect against experimental PAH, we sought to determine whether nitrite limits PASMC proliferation. Rat PASMCs were stimulated to proliferate by exposure to hypoxia (3% O 2 ) and PDGF BB . PDGF BB was added as a mitogen to stimulate proliferation more potently. Cells were incubated with low concentrations of nitrite (0 to 25 mol/L), and proliferation was determined by measuring [ 3 H]-thymidine incorporation after 24 hours. Nitrite dose-dependently (2.5, 10, and 25 mol/L) inhibited PASMC proliferation to levels of 81Ϯ9%, 63Ϯ11%, and 68Ϯ10% that of hypoxia/PDGF-stimulated controls (PϽ0.001; Figure 6A ). To elucidate the mechanism of nitrite-mediated inhibition of PASMC proliferation, the influence of allopurinol (100 mol/L) was investigated. Allopurinol had a minimal effect on hypoxia-induced PASMC proliferation but significantly reversed the inhibitory effect of nitrite (PϽ0.001; Figure  6B ). These data suggest that the antiproliferative effect of nitrite on PASMCs is dependent on XOR-mediated reduction of nitrite to NO.
Sodium Nitrite Inhibits PASMC Proliferation via p21 Waf1/Cip1
The inhibition of smooth muscle cell proliferation by NO is known to be dependent on the cyclin-dependent kinase inhibitor p21 Waf1/Cip1 . To determine whether the inhibition of PASMC proliferation by nitrite is dependent on this pathway, the influence of nitrite on p21 Waf1/Cip1 protein was determined. PASMCs were exposed to hypoxia (3% oxygen) with and without sodium nitrite (10 mol/L). Nitrite increased p21 Waf1/Cip1 protein compared with hypoxia alone ( Figure 7A ) Additionally, this increase in protein was inhibited by allopurinol. Of note, the nitrite-induced inhibition of smooth muscle cell proliferation or increase in cellular p21 Waf1/Cip1 protein levels was not influenced by inhibition of guanylyl cyclase (data not shown). These data further suggest that the inhibition of PASMC proliferation is dependent on the metabolism of nitrite to NO by XOR. To investigate whether nitrite-mediated inhibition of PASMC proliferation is dependent on p21 Waf1/Cip1 expression, the influence of nitrite on wild-type (S129) or cdkn1a Ϫ/Ϫ (p21 Waf1/Cip1 -knockout) mouse PASMC proliferation was determined. Nitrite inhibited wild-type PASMC thymidine incorporation (*Pϭ0.005; critical levelϭ0.017) but failed to inhibit cells harvested from cdkn1a Ϫ/Ϫ mice (Pϭ0.50; Figure  7B ). These data imply that nitrite-mediated inhibition of smooth muscle cell proliferation is dependent on NO signaling.
The contribution of p21 Waf1/Cip1 signaling to the therapeutic effects of nebulized nitrite in preventing hypoxia-induced PAH was determined. Age-matched S129 or cdkn11 Ϫ/Ϫ mice were randomized to normoxia or 10% oxygen for 4 weeks with or without once-per-week sodium nitrite nebulization (1.5 mg/min for 20 minutes). As expected, chronic hypoxia resulted in PAH as determined by RVP measurements and RV/LVϩS mass ratios (PϽ0.001; Figure 7C and 7D). Moreover, nitrite nebulization significantly inhibited the development of PAH in both the wild-type and cdkn11 Ϫ/Ϫ mice compared with untreated hypoxic control mice (PϽ0.001). However, the extent of protection was diminished in the cdkn11 Ϫ/Ϫ mice compared with the wild-type mice, suggesting that the p21 Waf1/Cip1 signaling pathway contributes partly to the effects of nitrite in vivo. 
Inhibition of XOR Reverses the Protective Effects of Nebulized Nitrite in Experimental PAH
Because XOR is responsible for reduction of nitrite to NO in the lung and nitrite-dependent reversal of PASMC proliferation, we hypothesized that inhibition of XOR would inhibit nitrite-dependent protection against the development of experimental PAH. C57BL/6 mice were fed a tungstensupplemented diet, which has previously been shown to inhibit XOR activity compared with control mice on standard chow. This diet was initiated 3 weeks before the onset of hypoxia (10% O 2 ) and maintained throughout the duration of the experiment. The inhibition of pulmonary XOR activity by dietary tungsten supplementation was confirmed ( Figure 8A ). In addition, studies confirmed that XOR enzymatic activity was increased after 3 weeks of monocrotaline treatment ( Figure 8B ). Nitrite therapy was initiated at the onset of hypoxia and was delivered as a nebulized treatment (1.5 mg/min for 20 minutes) once per week. Consistent with the above-mentioned studies, nitrite decreased RV/LVϩS to 0.26Ϯ0.01 compared with 0.32Ϯ0.05 in hypoxic controls (PϽ0.001), whereas the tungsten-enriched diet alone had minimal influence on hypoxia-induced PAH (RV/LVϩS ratioϭ0.32Ϯ0.06). However, dietary tungsten supplementation reversed the protective effects of nitrite in preventing the development of PAH (RV/LVϩS ratioϭ0.32Ϯ0.03; PϽ0.001 versus the hypoxic nitrite group; Figure 8C ). An additional genetic approach to examine the contribution of XOR would be ideal; however, XOR-null mice, which are phenotypically normal at birth, fail to thrive and do not live beyond 6 weeks of age. 44, 45 Consistent with our in vitro findings, these data suggest that XOR activity is necessary for nitrite-dependent protection.
Discussion
These data demonstrate that inhaled, low-dose nebulized nitrite both prevents and reverses experimental PAH and right heart failure in 2 distinct preclinical models. In vitro and in vivo experiments reveal a novel and potent antiproliferative effect of nitrite that is regulated by a reductase activity of lung XOR via NO-dependent signaling and expression of the cell-cycle check point inhibitor p21 Waf1/Cip1 .
Nitrite has recently been recognized as an important nonenzymatic blood and cellular reservoir of NO physiology Whole-blood, plasma, and pulmonary nitrite levels after nitrite nebulization. A through C, Baseline measurements of nitrite concentration were determined. Mice were then subjected to 20 minutes of nitrite nebulization (1.5 mg/min for 20 minutes) and placed in a hypoxic environment (10%). Nitrite concentration in whole blood (A) and plasma (B) was then determined over time (from 10 minutes to 24 hours after nebulization). C, After baseline pulmonary tissue nitrite concentration was determined, mice were subjected to nitrite nebulization (1.5 mg/min for 20 minutes) and then placed in either a normoxic (21%) or hypoxic (10%) environment. Tissue nitrite concentration was determined over time (5 minutes to 24 hours). All values are meanϮSD of at least 3 animals. *PϽ0.001 vs baseline. and therapeutics. Multiple studies have now shown that nitrite is cytoprotective and decreases tissue injury and apoptosis in mammalian models of ischemia/reperfusion involving the heart, brain, liver, or kidney. 34, 37, 39 In these previous models, protection from nitrite was dependent on metabolism to NO, and nitrite was delivered as a preconditioning agent or just before reperfusion.
Although our group has recently reported that high pharmacological doses of nitrite (0.5 mg to 30 mg/min nebulization) produce acute pulmonary vasodilation in an ovine model of hypoxia-induced pulmonary vasoconstriction and, to a lesser extent, in normoxic thromboxane-induced pulmonary vasoconstriction, no groups have explored the effects on low-dose chronic exposure to nitrite on proliferative and inflammatory pulmonary vasculopathy. 40 In the present study, nitrite is used as a therapeutic in a chronic injury model involving cellular proliferation and tissue remodeling. Of note, all RVP measurements in this study were done at least 24 hours after the last dose of nebulized nitrite; therefore, these results do not simply represent the influence of nitrite on pulmonary vasodilation. Surprisingly, low-dose nebulized nitrite delivered as little as once a week effectively prevented the development of pulmonary hypertension. Experimental exposure to treatment of low-dose nitrite 3 times per week after the establishment of PAH effectively reversed PAH in both hypoxic and monocrotaline models. We hypothesized that such "negative remodeling" in the reversal of PAH requires a loss of pulmonary vascular cell number or mass secondary to apoptosis, autophagy, or decreased cellular proliferation.
These studies investigated the effect of sodium nitrite on cellular proliferation and demonstrate that nitrite inhibits PDGF-and hypoxia-dependent PASMC proliferation in vitro. These data demonstrate an XOR-dependent increase in cyclin-dependent kinase inhibitor p21 Waf1/Cip1 protein levels induced by nitrite under hypoxic conditions. Additionally, nitrite fails to inhibit proliferation in PASMCs that are deficient in p21 Waf1/Cip1 . This is consistent with previous studies that demonstrate a central role for p21 Waf1/Cip1 protein in NO-mediated inhibition of smooth muscle cell prolifera- tion, 15, 16, 18, 46 thus further supporting that NO generated from the hypoxic metabolism of nitrite is central to the antiproliferative effects of nitrite signaling. However, although sodium nitrite does not significantly inhibit hypoxia-induced proliferation of PASMCs harvested from p21-null mice at the doses investigated, nebulized sodium nitrite effectively limits the development of chronic hypoxia-induced PAH in the p21-knockout mice. Interestingly, compared with the effects of nebulized nitrite on wild-type S129 mice, the level of protection was decreased in the p21-knockout mice. These data suggest that in vivo sodium nitrite is only partly dependent on p21 and cell-cycle regulation. This also suggests that other pathways, in addition to influences on proliferative pathways, contribute to the protective effects and negative vascular remodeling seen with nitrite therapy in these models.
It is increasingly apparent that a number of enzyme systems are capable of hypoxic conversion of nitrite to NO, depending on the organ system, regional oxygen tensions, and pH gradients. 29 In blood, nitrite reduction to NO is hypothesized to occur via an allosterically regulated nitrite reductase activity of deoxygenating hemoglobin. 30 In human blood flow studies, nitrite-dependent vasodilation is temporally coupled to the intraerythrocytic reduction of nitrite to NO and iron-nitrosylated hemoglobin. 47 This vasodilation is not inhibited by coinfusion of oxypurinol, an inhibitor of XOR, indicating that in the vascular compartment of the human forearm, XOR does not regulate vasodilation. Studies in the heart have revealed that Ϸ60% to 70% of NO generation from nitrite is mediated by the nitrite reductase activity of deoxymyoglobin, with the balance dependent on reduction by xanthine oxidase. 34 In the lung, the situation is reversed, as is evident in the present study, with Ͼ70% of nitrite reduction mediated by XOR. XOR is a molybdoflavin enzyme that is broadly distributed in mammalian tissues. Although the enzyme is well known as a source of superoxide generation under ischemic conditions, XOR has also been shown recently to reduce nitrite to NO at its molybdenum site. 33, 48, 49 This site is also responsible for the oxidation of purine substrates and is the binding site of the XOR inhibitors allopurinol or oxypurinol.
In the present studies, we show that hypoxia induces NO generation in lung homogenates incubated with nitrite in an XOR-dependent and hemoglobin-independent manner. These lung homogenates contain minimal hemoglobin because the majority of blood is removed at the time of tissue harvest. Additionally, there is relatively very little myoglobin present in lung tissue. Moreover, inhibition of XOR by allopurinol in PASMC proliferation studies diminished the antiproliferative Figure 7 . Nitrite inhibits PASMC proliferation via p21 Waf1/Cip1 . A, Nitrite (10 mol/L) increases p21 Waf1/Cip1 protein levels in hypoxic PASMCs. Allopurinol (100 mol/L) reverses nitrite-induced p21 Waf1/Cip1 protein. Western blot is representative, and histogram demonstrates the meanϮSD for 3 independent experiments (*PϽ0.001 vs control, #PϽ0.001 vs nitrite). B, Nitrite inhibits wild-type (S129; *PϽ0.001) but not p21 Waf1/Cip1knockout (cdkn11 Ϫ/Ϫ ) PASMC proliferation (Pϭ0.50; critical levelϭ0.05). Results are meanϮSD for 3 independent experiments, each performed in triplicate. C, Nebulized sodium nitrite (1.5 mg/min for 20 minutes, once per week) prevents the development of chronic hypoxia-induced PAH in both S129 and cdkn11 Ϫ/Ϫ mice (*PϽ0.001 vs respective normoxic controls; #Pϭ0.001 [critical levelϭ0.01];
§PϽ0.001 vs respective hypoxic controls). However, the degree of protection of nitrite treatment in hypoxia is diminished in the p21 Waf1/Cip1 -null mice vs the wild-type mice ( †Pϭ0.003; critical levelϭ0.007) (nϭ6 mice per group). effects of nitrite, and these cells in culture have no substantial levels of hemoglobin. Similarly, in our in vivo model, supplementation with tungsten, which inhibits XOR activity by replacing molybdenum in the active site, reverses the protective effects of nebulized nitrite on the development of PAH. Tungsten was used for these in vivo investigations because of its efficacy as an inhibitor of XOR activity and because allopurinol has been shown to have a multitude of effects on cardiac contractility and efficiency that may confound studies to determine the role of XOR as a nitrite reductase in this model. Although dietary tungsten supplementation effectively inhibits XOR activity, it is not a specific inhibitor of this enzyme and affects other enzymes containing molybdenum, including aldehyde oxidase, another enzyme that has been reported to possess nitrite reductase activity. Thus, conclusions about the dependency of nitrite specifically on XOR must be made with such considerations. However, genetic approaches to manipulate this enzyme are difficult because of the lethality of XOR-null mice and the difficulty in effectively or specifically knocking down XOR in the pulmonary vasculature.
The approach of using nebulized nitrite as a strategy to augment pulmonary vascular NO levels has several potential advantages compared with traditional methods of increasing NO such as inhaled NO therapy. Delivery of sodium nitrite as a nebulized treatment is simple and could be easily implemented as a modality of therapy. The approach is also appealing in that an intermittent low dose is used as a relatively brief clinical treatment in these experimental models. Furthermore, low-dose nebulized nitrite likely has a safer toxicity profile and more specificity compared with inhaled NO. However, with regard to the known toxicity of sodium nitrite (LD 50 , 180 mg/kg in rats), these data measuring whole-blood, plasma, and lung levels of nitrite ( Figure 4 ) demonstrate that the dose actually delivered to the animals is low. Additionally, initial dosing studies performed as part of these investigations suggest that very low doses of sodium nitrite have a therapeutic effect. Together, these data indicate that the protective effects of nitrite are occurring as low-dose biological effects, well below levels shown to be toxic.
Another particularly interesting aspect of nitrite therapy is the potential specificity of nitrite as an NO-releasing species. The hypothesis is that relatively low levels of nitrite can be delivered to tissues and that this nitrite will release NO only if conditions in the local environment favor the generation of NO. Particularly hypoxic conditions and those of low pH favor reduction. This is demonstrated by our study in mice in which nebulized nitrite increases pulmonary nitrite levels under normoxic conditions, but pulmonary nitrite levels do not increase if mice are placed in a hypoxic environment (10% oxygen). These data suggest that in hypoxia the lack of an increase in pulmonary nitrite levels is due to the metabolism of nitrite to NO, which implies increased nitrite reductase activity under hypoxic conditions. Interestingly, pulmonary nitrite levels were significantly decreased from baseline values in mice that were placed into hypoxia at 240 and 300 Figure 8 . Nitrite-mediated protection against hypoxia-induced PAH is dependent on XOR activity as determined by RV/LVϩS ratios. A, XOR activity was increased after 1 week of hypoxia (10% oxygen; *PϽ0.001; nϭ4 mice per group) and was effectively inhibited by a tungsten-enriched diet (#PϽ0.001). B, XOR activity in pulmonary tissue is increased 3 weeks after monocrotaline treatment (*PϽ0.001; nϭ4 rats per group). C, Hypoxia-induced PAH (*PϽ0.001 vs normoxic controls) was inhibited by nebulized nitrite as previously demonstrated (#PϽ0.001 vs hypoxic controls). A tungsten-enriched diet diminished the protective effects of nebulized nitrite (nϭ8 mice per group;
§PϽ0.001 vs nitrite-treated hypoxic mice).
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minutes after nitrite nebulization; these values returned to baseline by 24 hours. This significant decrease in pulmonary nitrite levels may be secondary to increased pulmonary nitrite reductase activity after the initiation of hypoxia. We hypothesize that the nitrite reductase activity would be due mainly to increased XOR activity. We further hypothesize that pulmonary nitrite levels return to baseline values by 24 hours secondary to compensatory increased NO production by NO synthase enzymes and subsequent metabolism.
Conclusions
Using 2 distinct models of pulmonary hypertension, we show the following. First, inhaled nitrite delivered as low-dose, 20-minute nebulized treatment either 1 or 3 times per week can prevent or reverse PAH, resulting in decreased pulmonary artery muscularization, RVPs, and RV hypertrophy. Second, nebulized nitrite achieves low pulmonary and systemic levels of nitrite; however, in the setting of hypoxia, nitrite levels do not increase in the lung. Incubation of lung homogenates with nitrite leads to the generation of NO, which is inhibited by allopurinol. These data suggest that XOR is responsible for the hypoxic metabolism of nitrite to NO within the lung. Third, the protection of nitrite against the development of hypoxia-induced PAH is reversed by XOR inhibition, further suggesting an important role for this enzyme in the mechanism of protection of nebulized nitrite in this model. Nebulized nitrite has the promise of being an effective clinical adjunct in the treatment of patients with PAH. Clinical studies already suggest a role for NO-based therapeutics for this disease process. However, further studies are required to better characterize the dosing and potential toxicities of nebulized nitrite and to further delineate the mechanism of action of nitrite as a therapeutic.
